| Oct 31 |
Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences
|
| Oct 23 |
ChromaDex Leads The Charge With 2 Other US Penny Stocks To Watch
|
| Oct 1 |
Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
|
| Aug 8 |
Barinthus Biotherapeutics GAAP EPS of -$0.43 misses by $0.03
|
| Aug 8 |
Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results
|
| Aug 1 |
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
|
| Jun 6 |
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
|
